One World Trade Center to be lit up in green in observance of Mental Health MonthNEW YORK, May 01, 2023...
UHC Medicare Advantage plans in NGS states expand access via NPPsMALVERN, Pa., April 28, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc....
MALVERN, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on...
The application is for a novel psychedelic-based combination, of Clearmind's MEAI and SciSparc's Cannamide™ Tel Aviv, Israel / Vancouver, Canada,...
The application refers to a novel psychedelic-based combination of Clearmind's MEAI and SciSparc's Cannamide™ TEL AVIV, Israel, April 21, 2023 (GLOBE NEWSWIRE)...
NEW YORK, April 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
First large-scale digital roll out of Baycrest’s Goal Management Training will support mental rehabilitation for people across Canada and the...
Cuvrior™ now available in the US for the treatment of adult patients with stable Wilson disease who are de-coppered and...
Medication failure leads 45% of respondents with depression and/or anxiety to turn to unhealthy coping mechanisms Respondents may view these behaviors...
Healthcare supply chain software company plans to donate 5% of all proceeds to charitiesDALLAS, April 14, 2023 (GLOBE NEWSWIRE) --...
BlueCross BlueShield of Mississippi Latest to Allow Non-Physician Practitioners to Prescribe TMSMALVERN, Pa., April 13, 2023 (GLOBE NEWSWIRE) -- Neuronetics,...
“The Invisible Machine” reveals the startling truth about trauma and the scientific breakthrough that could transform millions of lives The...
SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced...
New investor Koch Disruptive Technologies joins existing investors to reinforce Oshi’s market lead and address surging demand from patients, employers,...
— Presentation entitled "BMB-101: A selective 5-HT2C agonist in clinical trials with therapeutic utility" — — First-in-human Phase 1 trial for lead program,...
CENTER CITY, Minn. and VANCOUVER, British Columbia, April 05, 2023 (GLOBE NEWSWIRE) -- The Hazelden Betty Ford Foundation and TELUS...
MALVERN, Pa., April 04, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a...
Approximately two-thirds of trial patients with Major Depressive Disorder achieving remission following SPL026 treatment sustained remission to six-months Aggregated Remission...
DENVER, March 31, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"),...
VANCOUVER, British Columbia, March 29, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. (“Lucy” or “The Company”) , an early-stage...